Charles Schwab Investment Management Inc. lowered its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,397,511 shares of the company's stock after selling 37,886 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.95% of MiMedx Group worth $13,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in MiMedx Group by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock valued at $16,518,000 after buying an additional 44,254 shares during the last quarter. Bank of New York Mellon Corp increased its position in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock valued at $4,849,000 after acquiring an additional 3,300 shares during the last quarter. Disciplined Growth Investors Inc. MN boosted its position in MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company's stock worth $2,100,000 after purchasing an additional 2,737 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of MiMedx Group by 11.8% during the 3rd quarter. Wellington Management Group LLP now owns 317,274 shares of the company's stock valued at $1,875,000 after purchasing an additional 33,461 shares during the period. Finally, Jane Street Group LLC increased its position in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after purchasing an additional 174,797 shares during the last quarter. 79.15% of the stock is owned by institutional investors.
MiMedx Group Stock Performance
NASDAQ:MDXG traded down $0.20 during mid-day trading on Tuesday, hitting $7.90. 372,198 shares of the company traded hands, compared to its average volume of 693,292. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The stock's fifty day moving average price is $8.36 and its 200-day moving average price is $7.88. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 14.36 and a beta of 1.97. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares of the company's stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last three months. 1.30% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.
Read Our Latest Stock Analysis on MiMedx Group
MiMedx Group Profile
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
